Furthermore, a subset of biopsy samples from heavily pretreated ER+ breast cancer patients treated with zotatifin in ongoing clinical trials (ClinicalTrials.gov NCT04092673) showed induction of many of the ISGs compared with pretreatment (Figure 5B and Supplemental Figure 4D). This evidence concerns the gene ESR1 and breast carcinoma.